Psychosocial aspects of genetic screening of pregnant women and newborns: A systematic review

Health Technology Assessment

Volumn 8, Issue 33, 2004, Pages

  Green, J M ^a   Hewison, J ^a   Bekker, H L ^a   Bryant, L D ^a   Cuckle, H S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA FETOPROTEIN; CHOLESTEROL; HEMOGLOBIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ACCURACY; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANXIETY; CHROMOSOME ABERRATION; COPING BEHAVIOR; CYSTIC FIBROSIS; DOWN SYNDROME; DUCHENNE MUSCULAR DYSTROPHY; ECHOGRAPHY; ETHNIC GROUP; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; FRAGILE X SYNDROME; GENETIC DISORDER; GENETIC SCREENING; HEALTH CARE QUALITY; HEMOGLOBINOPATHY; HUMAN; HYPOTHYROIDISM; INFORMATION PROCESSING; INFORMED CONSENT; INSULIN DEPENDENT DIABETES MELLITUS; INTERVIEW; MATERNAL BEHAVIOR; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RECORD; MEDICAL RESEARCH; METHODOLOGY; MINORITY GROUP; NEURAL TUBE DEFECT; NEWBORN SCREENING; PATIENT ATTITUDE; PHENYLKETONURIA; PREGNANCY; PRENATAL PERIOD; QUESTIONNAIRE; REVIEW; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; TAY SACHS DISEASE; VIDEOTAPE;

EID: 4544322158     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta8330     Document Type: Review

References (171)

1. Green JM. Calming or harming? A critical review of psychological effects of fetal diagnosis on pregnant women. London: Galton Institute, Occasional Papers, Second Series, No. 2; 1990.
2. Green JM. Women's experiences of prenatal screening and diagnosis In Abramsky L, Chapple J, editors. Prenatal diagnosis: the human side, 2nd ed. Cheltenham: Nelson Thornes. 2003. pp. 37-53.
3. Green JM, Statham H. Psychosocial aspects of prenatal screening and diagnosis. In Marteau TM, Richards MPM, editors. The troubled helix: social and psychological implications of the new human genetics. Cambridge: Cambridge University Press; 1996. pp. 140-63.
4. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. Health Technol Assess 1998;2(l).
5. Bricker L, Garcia J, Henderson J, Mugford M, Neilson J, Roberts T, et al. Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views. Health Technol Assess 2000;4(16).
6. Nicolaides KH, Snijders RJM, Gosden CM, Berry C, Campbell S. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 1992;340:704-7.
7. Richards MPM, Green JM. Attitudes toward prenatal screening for fetal abnormality and detection of carriers of genetic disease: a discussion paper. J Reprod Infant Psychol 1993; 11:49-56.
8. Farrant W. Stress after amniocentesis for high serum alpha-feto-protein concentrations. BMJ 1980;281:452.
9. Fearn J, Hibbard BM, Laurence KM, Roberts A, Robinson JO. Screening for neural-tube defects and maternal anxiety. Br J Obstet Gynaecol 1982; 89:218-21.
10. Berne-Fromell K, Uddenberg N, Kjessler B. Psychological reactions experienced by pregnant women with an elevated serum alpha-fetoprotein level. J Psychosomatic Obstet Gynaecol 1983;2:233-7.
11. Burton BK, Dillard RG, Clark EN. The psychological impact of false positive elevations of maternal serum alpha-fetoprotein. Am J Obstet Gynaecol 1985;151:77-82.
12. Marteau TM, Cook R, Kidd J, Michie S, Johnston M, Slack J, et al. The psychological effects of false positive results in prenatal screening for fetal abnormality: a prospective study. Prenat Diagn 1992;12:205-14.
13. Green JM. Serum screening for Down's syndrome: the experiences of obstetricians in England & Wales. BMJ 1994;309:769-72.
14. Berne-Frommel K, Kjessler B, Josefson G. Anxiety concerning fetal malformation in women who accept or refuse alpha-fetoprotein screening in pregnancy. J Psychosom Obstet Gynaecol 1983;2:94-7.
15. Berne-Frommel K, Kjessler B. Anxiety concerning fetal malformations in pregnant women exposed or not exposed to an antenatal serum alpha-fietoprotein screening program. Gynaecol Obstet Invest 1984;17:36-9.
16. Burton BK, Dillard RG, Clark EN. Maternal serum alpha-fetoprotein screening: the effect of participation on anxiety and attitude toward pregnancy in women with normal results. Am J Obstet Gynecol 1985;152:540-3.
17. Marteau TM, Johnston M, Kidd J, Michie S, Cook R, Slack J, et al. Psychological models in predicting uptake of prenatal screening. Psychol Health 1992;6:13-22.
18. Statham H, Green J, Snowdon C. Psychological and social aspects of screening for fetal abnormality during routine antenatal care. In Robinson S, Thomson A, Tickner V, editors. Proceedings of the 1992 Research and the Midwife Conference. Manchester: School of Nursing. University of Manchester; 1993. pp. 44-62.
19. Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X syndrome. Health Technol Assess 1997;1(4).
20. Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1(7).
21. Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997;1(11).
22. Bekker H, Thornton JG, Airey CM, Connelly JB, Hewison J, Lilleyman J, et al. Informed decision making: an annotated bibliography and systematic review; Health Technol Assess 1994;3(1).
23. Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J. Screening for cystic fibrosis. Health Technol Assess 1999;3(8).
24. Zeuner D, Ades AE, Karnon J, Brown J, Dezateaux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK. review and economic analysis. Health Technol Assess 1999;3(11).
25. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000; 4(3).
26. Petticrew MP, Snowden AJ, Lister-Sharp D, Wright K. False-negative results in screening programmes: systematic review of impact and implications. Health Technol Assess 2000;4(5).
27. Marteau TM, Johnston M, Plenicar M, Shaw RW, Slack J. Development of a self-administered questionnaire to measure women's knowledge of prenatal screening and diagnostic tests. J Psychosom Res 1988;32:403-8.
28. Statham H, Green J, Snowdon C. Mothers' consent to screening newborn babies for disease. BMJ 1993;306:858-9.
29. Bekker HL. Decision making and prenatal testing. PhD thesis, University of Leeds; 1999.
30. Middleton A. Attitudes of deaf and hearing individuals towards issues surrounding genetic testing for deafness. PhD thesis, University of Leeds; 1999.
31. Ahmed S. Thalassaemia carrier testing in pregnant Pakistani women: perceptions of 'information' and 'consent'. PhD thesis, University of Leeds; 2002.
32. Bryant LD. Understandings of Down's syndrome in the prenatal testing context. PhD thesis, University of Leeds; 2003.
33. Marteau TM. Towards informed decisions about prenatal testing: a review. Prenat Diagn 1995; 15:1215-26.
34. Jepson R, Clegg.A. Forbes C, Lewis R, Sowden A, Kleijnen J. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technol Assess 2000;4(14).
35. Murphy E, Dingwall R, Greatbach D, Parker S, Watson P. Qualitative research methods in health technology assessment: a review of the literature. Health Technol Assess 1998;2(16).
36. Collins RF, Bekker HL, Dodwell DJ. Follow-up care of patients treated for breast cancer: a structured review. Cancer Treat Rev 2004;30:19-35.
37. Smith DK, Shaw RW, Marteau TM. Informed consent to undergo serum screening for Down's syndrome: the gap between policy and practice. BMJ 1994;309:776.
38. Freda MC, DeVore N, Valentine-Adams N, Bombard A, Merkatz IR. Informed consent for maternal serum alpha-fetoprotein screening in an inner city population: how informed is it? J Obst Gynecol Neonatal Nurs 1998;27:99-106.
39. Grewal GK, Moss HJ, Aitken DA, Bjornsson S, Cameron AD, Pell JP. Factors affecting women's knowledge of antenatal serum screening. Scot Med J 1997;42:111-13.
40. Glazier R, Goel V, Holzaplel S, Summers A, Pugh P, Yeung M. Written patient information about triple marker screening: a randomised controlled trial. Obstet Gynecol 1997;90:769-74.
41. Chilaka VN, Konje JC, Stewart CR, Narayan H, Taylor DJ. Knowledge of Down syndrome in pregnant women from different ethnic groups. Prenat Diagn 2001;21:159-64.
42. Mulvey S, Wallace EM. Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. Br J Obstet Gynaecol 2000;107:1302-5.
43. Marteau TM, Kidd J, Michie S, Cook R, Johnston M, Shaw RW. Anxiety, knowledge and satisfaction in women receiving false positive results on routine prenatal screening - a randomized controlled trial. J Psychosom Obst Gynaecol 1993;14:185-96.
44. Graham W, Smith P, Kamal A, Fitzmaurice A, Smith N, Hamilton N. Randomised controlled trial comparing effectiveness of touch screen system with leaflet for providing women with information on prenatal tests. BMJ 2000; 320:155-60.
45. Michie S, Smith D, Marteau TM. Prenatal tests: how are women deciding? Prenat Diagn. 1999; 19:743-8.
46. Goel V, Glazier R, Holzapfel S, Pugh P, Summers A. Evaluating patient's knowledge of maternal serum screening. Prenat Diagn 1996;16:425-30.
47. Ormond KE, Pergament E, Fine BA. Pre-screening education in multiple marker screening programs: the effect on patient anxiety and knowledge. J Genet Couns 1996;5:69-80.
48. Michie S, Smith D, McClennan A, Marteau TM. Patient decision making: an evaluation of two different methods of presenting information about a screening test. Br J Health Psychol 1997;2:317-26.
49. Thornton JG, Hewison J, Lilford RJ, Vail A. A randomised trial of three methods of giving information about prenatal testing. BMJ 1995; 311:1127-30.
50. Press N, Browner CH. Characteristics of women who refuse an offer of prenatal diagnosis: data from the California maternal serum alpha fetoprotein blood test experience. Am J Med Genet 1998;78:433-45.
51. Santalahti P, Aro AR, Hemminki E, Helenius H, Ryynanen M. On what grounds do women participate in prenatal screening? Prenat Diagn 1998;18:153-65.
52. Heikkila A, Ryynanen M, Kirkinen P, Saarikoski S. Results and views of women in population-wide pregnancy screening for trisomy 21 in east Finland. Fetal Diagn Ther 1997;12:93-6.
53. Moyer A, Brown B, Gates E, Daniels M, Brown HD, Kuppermann M. Decisions about prenatal testing for chromosomal disorders: perceptions of a diverse group of pregnant women. J Womens Health Gender-Based Med 1999;8:521-31.
54. Browner CH, Preloran M, Press NA. The effects of ethnicity, education and an informational video on pregnant women's knowledge and decisions about a prenatal diagnostic screening test. Patient Educ Couns 1996;27:135-46.
55. Salonen R, Kurki L, Lappalainen M. Experiences of mothers participating in maternal serum screening for Down's syndrome. Eur J Hum Genet 1996;4:113-19.
56. Gekas J, Gondry J, Mazur S, Cesbron P, Thepot F. Informed consent to serum screening for Down syndrome: are women given adequate information? Prenat Diagn 1999;19:1-7.
57. Carroll JC, Brown JB, Reid AJ, Pugh P. Women's experience of maternal serum screening. Can Fam Physician 2000;46:614-20.
58. Al-Jader LN, Parry-Langdon N, Smith RJ. Survey of attitudes of pregnant women towards Down syndrome screening. Prenat Diagn 2000;20:23-9.
59. Statham H, Green J. Serum screening for Down's syndrome: some women's experiences. BMJ 1993; 307:174-6.
60. Roelofsen E-E, Kamerbeek L-I, Tymstra Tj. Chances and choices: psycho-social consequences of maternal serum screening: a report from The Netherlands. J Reprod Infant Psychol 1993;11:41-7.
61. Priest JH, Fitzgerald JM, Haag MM, Streets K, Vanisko M, Johnson JP. Acceptance of amniocentesis by women in the state of Montana (USA) who are screen positive for Down's syndrome. J Med Screen 1998;5:178-82.
62. Marteau TM, Saidi G, Goodburn S, Lawton J, Michie S, Bobrow M. Numbers or words? A randomized controlled trial of presenting screen negative results to pregnant women. Prenat Diagn 2000;20:714-18.
63. Hewison J, Cuckle H, Baillie C, Sehmi I, Lindow S, Jackson F, et al. Use of videotapes for viewing at home to inform choice in Down syndrome screening: a randomised controlled trial. Prenat Diagn 2001;21:146-9.
64. Weinans MJ, Huijssoon AM, Tymstra T. Gerrits MC, Beekhuis JR, Mantingh A. How women deal with the results of serum screening for Down syndrome in the second trimester of pregnancy. Prenat Diagn 2000;20:705-8.
65. Robinson J. Prenatal screening: a retrospective study. Br J Midwifery 2001;9:412-17.
66. Royal College of Obstetricians and Gynaecologists. Report of the working party on biochemical markers and the detection of Down's syndrome. London: RCOG Press; 1993.
67. Spielberger C, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. State-trait anxiety inventory: STAI form Y. Palo Alto, CA: Consulting Psychologists Press; 1970.
68. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger state-trait anxiety inventory (STAI). Br J Clin Psychol 1992;31:301-6.
69. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-70.
70. Ley P, Llewellyn S. Improving patients' understanding, recall, satisfaction and compliance. In Broome A, Llewellyn S, editors. Health psychology: processes and applications. 2nd ed. London: Chapman and Hall; 1995; Chapter 5.
71. Johnston M. Hospitalisation in adults. In Baum A, Newman S, Weinman J, West, R, McManus C, editors. Cambridge handbook of psychology, health and medicine. Cambridge: Cambridge University Press; 1997. pp. 121-3.
72. Bekker HL, Hewison J, Thornton JG. Understanding why decision aids work: linking process with outcome. Patient Educ Couns 2003; 50:323-9.
73. Schwarzer R, Quast H-H, Jerusalem M. The impact of anxiety and self-consciousness on cognitive appraisals in the achievement process. In Schwarzer R, van der Ploeg HM, Spielberger CD, editors. Advances in test anxiety research, Vol. 5. Lisse: Swets & Zeitlinger; 1987. pp. 39-52.
74. Bekker HL, Legare F, Stacey D, O'Connor A, Lemyre L. Is anxiety a suitable measure of decision aid effectiveness: a systematic review? Patient Educ Couns 2003,50:255-62.
75. Evans MI, Bottoms SF, Carlucci T, Grant J, Belsky RL, Solyom AE, et al. Determinants of altered anxiety after abnormal maternal serum alpha-fetoprotein screening. Am J Obstet Gynecol 1988;159:1501-4.
76. Marteau TM, Kidd J, Cook R, Johnston M, Michie S, Shaw RW, et al. Screening for Down's syndrome. BMJ 1988;297:1469.
77. Quagliarini D, Betti S, Brambati B, Nicolini U. Coping with serum screening for Down syndrome when the results is given as a numeric value. Prenat Diagn 1998;18:816-21.
78. Abuelo DN, Hopmann MR, Barsel-Bowers G, Goldstein A. Anxiety in women with low maternal serum alpha-fetoprotein screening results. Prenat Diagn 1991;11:381-5.
79. Keenan KL, Basso D, Goldkrand J, Butler WJ. Low level of maternal serum alpha-fetoprotein: its associated anxiety and the effects of genetic counselling. Am J Obstet Gynecol 1991;164:54-6.
80. Santalahti P, Latikka AM, Ryynanen M, Hemminki E. Women's experiences of prenatal serum screening. Birth 1996;23:101-7.
81. Jorgensen FS. User acceptability of an alpha-fetoprotein screening programme. Dan Med Bull 1995;42:100-5.
82. Santalahti P, Hemminki E, Latikka AM, Ryynanen M. Women's decision-making in prenatal screening. Soc Sci Med 1998;46:1067-76.
83. Burn J, Fairgrieve S, Franks P, White I, Magnay D. Audit of maternal serum screening: strategies to augment counselling in response to women's views. Eur J Hum Genet 1996;4:108-12.
84. Dodds R, Newburn M. Support during screening - an NCT report. Mod Midwife 1997;7:23-6.
85. Alteneder RR, Kenner C, Greene D, Pohorecki S. The lived experience of women who undergo prenatal diagnostic testing due to elevated maternal serum alpha-fetoprotein screening. Am J Maternal Child Nurs 1998;23:180-6.
86. Jan S-W, Chen C-P, Huang L-H, Huang F-Y, Lan C-C. Attitudes toward maternal serum screening in Chinese women with positive results. J Genet Couns 1996;5:169-80.
87. Rausch ND, Lambert-Messerlain GM, Canick JA. Participation in maternal serum screening following screen positive results in previous pregnancy. J Med Screen 2000;7:4-6.
88. Wald NG. Couple screening for cystic fibrosis. Lancet 1991;338:1318-19.
89. Mennie ME, Liston WA, Brock DJH. Prenatal cystic fibrosis carrier testing: designing an information leaflet to meet the specific needs of the target population. J Med Genet 1992; 29:308-12.
90. Livingstone J, Axton RA, Mennie M, Gilfillan A, Brock DJH. A preliminary trial of couple screening for cystic fibrosis: designing an appropriate information leaflet. Clin Genet 1993, 43:57-62.
91. Mennie ME, Compton ME, Gilfillan A, Liston WA, Pullen I, Whyte DA, et al. Prenatal screening for cystic fibrosis: psychological effects on carriers and their partners. J Med Genet 1993;30:543-8.
92. Witt DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, et at. Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 1996;58:823-35.
93. Jung U, Urner U, Grade K, Coutelle C. Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population. Hum Genet 1994;94:19-24.
94. Miedzybrodzka ZH, Hall MH, Mollison J, Templeton A, Russell IT, Dean JC, et al. Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ 1995; 310:353-7.
95. Grody WW, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Fang CY, Cantor RM, et al. PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet 1997;60:935-47.
96. Cuckle H, Quirke P, Sehmi T, Lewis F, Murray J, Cross D, et al. Antenatal screening for cystic fibrosis. Br J Obstet Gynaecol 1996;103:795-9.
97. Leonard KP, Bartholomew LK, Swank PR, Parcel GS. A comparison of two approaches to education about carrier testing for cystic fibrosis. J Genet Couns 1995;4:97-113.
98. Mennie M, Compton M, Gilfillan A, Axton RA, Liston WA, Pullen I, et al. Prenatal screening for cystic fibrosis: attitudes and responses of participants. Clin Genet 1993;44:102-6.
99. Mennie ME, Axworthy D, Liston WA, Brock DJH. Prenatal screening for cystic fibrosis carriers: does the method of testing affect the longer-term understanding and reproductive behaviour of women? Prenat Diagn 1997;17:853-60.
100. Clausen H, Brandt NJ, Schwartz M, Skovby F. Psychological and social impact of carrier screening for cystic fibrosis among pregnant woman - a pilot study. Clin Genet 1996;49:200-5.
101. Hartley NE, Scotcher D, Harris H, Williamson P, Wallace A, Craufurd D, et al. The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 1997;34:459-64.
102. Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R. Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice. Br J Gen Pract 1996;46:225-7.
103. Rowley PT, Loader S, Walden M. Pregnant women identified as hemoglobinopathy carriers by prenatal screening want genetic counselling and use information provided. Birth Defects: Original Article Series 1988;23:449-54.
104. Wallerstein R, Seshadri K, Brady-Yasbin S, Shih L. A retrospective survey of community based utilization of Tay Sachs screening in eight New Jersey counties. J Genet Couns 1994;3:125-31.
105. Loader S, Sutera CJ, Walden M, Kozyra A, Rowley PT. Prenatal screening for hemoglobinopathies II. Evaluation of counselling. Am J Hum Genet 199 1;48:447-51.
106. Green J, France-Dawson M. Women's experiences of routine screening during pregnancy: the sickle cell study. Targeting health promotion: reaching those in the West Midlands. In Clarke A, Parsons E, editors. Culture, kinship and genes: towards cross-cultural genetics. New York: St. Martin's Press; 1997. pp. 120-32.
107. Rowley PT, Loader S, Sutera CJ, Walden M, Kozyra A. Prenatal screening for hemoglobinopathies III. Applicability of the health belief model. Am J Hum Genet 1991;48:452-9.
108. Rowley PT, Loader S, Sutera CJ, Walden M, Kozyra A. Prenatal screening for hemoglobinopathies I. A prospective regional trial. Am J Hum Genet 1991;48:439-46.
109. Green JM, Statham H, Snowdon C. Women's knowledge of prenatal screening tests. 1: Relationships with hospital screening policy and demographic factors. J Reprod Infant Psychol 1993;11:11-20.
110. Livingstone J, Axton RA, Gilfillan A, Mennie M, Compton M, Liston WA, et al. Antenatal screening for cystic fibrosis: a trial of the couple model. BMJ 1994;308:1459-62.
111. Al-jader LN, Goodchild MC, Ryley HC, Harper PS. Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin Genet 1990;38:460-5.
112. Hall S, Bobrow M, Marteau TM. Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study. BMJ 2000; 320:407-12.
113. Kornman LH, Wortelboer MJ, Beekhuis JR, Morssink LP, Mantingh A. Women's opinions and the implications of first- versus second-trimester screening for fetal Down's syndrome. Prenat Diagn 1997; 17:1011-18.
114. Press N, Browner CH. Why women say yes to prenatal diagnosis. Soc Sci Med 1997;45:979-89.
115. Jorgensen FS. Declining an alpha-fetoprotein test in pregnancy, why and who? Acta Obstet Gynecol Scand 1995;74:3-11.
116. Santalahti P, Hemminki E, Aro AR, Helenius H, Ryynanen M. Participation in prenatal screening tests and intentions concerning selective termination in Finnish maternity care. Fetal Diagn Ther 1999;14:71-9.
117. Markens S, Browner CH, Press N. 'Because of the risks': how US pregnant women account for refusing prenatal screening. Soc Sci Med 1999; 49:359-69.
118. Esen UI, Olajide F. Expectations and fears of women regarding two methods of prenatal screening. Int J Gynaecol Obstet 1997;57:193-4.
119. Phillips OP, Seely L, Wan JY, Wachtel SS, Shulman LP, A survey of attitudes about maternal serum screening for fetal chromosome abnormalities in women 35 years of age and older. Fetal Diagn Ther 1998;13:357-60.
120. Fairgrieve S. Screening in pregnancy. Screening for Down's syndrome: what the women think. Br J Midwifery 1997;5:148-51.
121. Jorgensen FS. Attitudes to prenatal screening, diagnosis and research among pregnant women who accept or decline an alpha-fetoprotein test. Prenat Diagn 1995;15:419-29.
122. Browner CH, Press NA. The normalization of prenatal diagnostic screening. In Ginsburg F, Rapp R, editors. Conceiving the new world order: the global politics of reproduction. Berkeley, CA: University of California Press; 1995. pp. 307-22.
123. Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr, et al. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 1996;59:234-47.
124. Fang CY, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Bass HN, Crandall BF, et al. Attitudes toward genetic carrier screening for cystic fibrosis among pregnant women: the role of health beliefs and avoidant coping style. Womens Health 1997; 3:31-51.
125. Mennie ME, Compton ME, Liston WA, Brock DJH. Gene therapy for cystic fibrosis: will it affect the uptake of prenatal carrier screening. Prenat Diagn 1994;14:1158-62.
126. Mennie ME, Gilfillan A, Compton ME, Liston WA, Brock DJ. Prenatal cystic fibrosis carrier screening: factors in a woman's decision to decline testing. Prenat Diagn 1993;13:807-14.
127. O'Connor AM, O'Brien-Pallas LL. Decisional conflict. In McFarland GK, McFarlane EA, editors. Nursing, diagnosis and intervention. Toronto: Mosby; 1989. pp. 486-96.
128. Charles C, Whelan T, Gafni A. What do we mean by partnership in making decisions about treatment? BMJ 1999;319:780-2.
129. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect 2001;4:99-108.
130. O'Connor AM. Validation of a decision conflict scale. Med Decis Making 1995;15:25-30.
131. Holmes-Rovner M, Krol J, Schmitt N, Rovner DR, Breer ML, Rothert ML, et al. Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Making 1996;16:58-64.
132. Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns 2002;48:87-91.
133. Baron J. Thinking and deciding. 2nd ed. Cambridge: Cambridge University Press; 1994.
134. Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE. Couple-based prenatal screening for cystic fibrosis in primary care settings. Prenat Diagn 1996;16:397-404.
135. Bekker HL. Genetic testing: facilitating informed choices. In Cooper DN, Thomas N, editors. Nature encyclopaedia of the human genome. New York: Nature; 2003. pp. 926-30.
136. Payne D. Couple has the right to refuse test on newborn child. BMJ 2001;323:1149.
137. Baroni MA, Anderson YE, Mischler E. Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatr Nurs 1997;23:143-51.
138. Boland C, Thompson NL. Effects of newborn screening of cystic fibrosis on reported maternal behaviour. Arch Dis Child 1990;65:1240-4.
139. Helton J, Harmon RJ, Robinson N, Accurso FJ. Parental attitudes toward newborn screening for cystic fibrosis. Pediatr Pulmon Suppl 1991;7:23-8.
140. Holtzman NA, Faden R, Chwalow AJ, Horn SD. Effect of informed parental consent on mothers' knowledge of newborn screening. Pediatrics 1983; 72:807-12.
141. Faden R, Chwalow AJ, Holtzman NA. Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. Am J Public Health 1982;72:1347-52.
142. Mischler EH, Wilfond BS, Fost N, Laxova A, Reiser C, Sauer CM, et al. Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998;102:44-52.
143. Tluczek A, Mischler EH, Farrell PM, Fost N, Peterson NM, Carey P. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. Dev Behav Pediatr 1992; 13:181-6.
144. Tluczek A, Mischler EH, Bowers B, Peterson NM, Morris ME, Farrell PM, et al. Psychological impact of false-positive results when screening for cystic fibrosis. Pediatr Pulmon Suppl 1991;7:29-37.
145. Bodegard G, Fyro K, Larsson A. Psychological reactions in 102 families with a newborn who has a falsely positive screening test for congenital hypothyroidism. Acta Paediatr Scand 1983; 304:1-21.
146. Fyro K, Bodegard G. Difficulties in psychological adjustment to a new neonatal screening programme. Acta Paediatr Scand 1988;77:226-31.
147. Fyro K, Bodegard, G. Four-year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism. Acta Paediatr Scand 1987;76:107-14.
148. Fyro K. Neonatal screening: life stress scores in families given a false positive result. Acta Paediatr Scand 1988;77:232-8.
149. Tymstra T. False positive results in screening tests: experiences of parents of children screened for congenital hypothyroidism. Fam Pract 1986;3:92-6.
150. Green JM, Murton FE. Diagnosis of Duchenne muscular dystrophy: parents' experiences and satisfaction. Child Care Health Dev 1996;22:113-28.
151. Hildes E, Jacobs HK, Cameron A, Seshia SS, Booth F, Evans JA. Impact of genetic counselling after neonatal screening for Duchenne muscular dystrophy. Am J Med Genet 1993;30:670-4.
152. Parsons E, Bradley D, Clarke A. Disclosure of Duchenne muscular dystrophy after newborn screening. Arch Dis Child 1996;74:550-3.
153. Bradley DM, Parsons EP, Clarke AJ. Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 1993;306:357-60.
154. Grossman LK, Holtzman NA, Charney E, Schwartz AD. Neonatal screening and genetic counselling for sickle cell trait. Am J Dis Child 1985;139:241-4.
155. Warren NS, Carter TP, Humbert JR, Rowley PT. Newborn screening for hemoglobinopathies in New York State: experience of physicians and parents of affected children. J Pediatr 1982; 100:373-7.
156. Yu MS, Norris JM, Mitchell CM, Butler-Simon N, Groshek M, Follansbee D, et al. Impact on maternal parenting stress of receipt of genetic information regarding risk of diabetes in newborn infants. Am J Med Genet 1999;86:219-26.
157. Senior V, Marteau TM, Peters TJ. Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents' responses to neonatal screening for familial hypercholesterolaemia. Soc Sci Med 1999; 48:1857-60.
158. 1 antitrypsin deficiency. Parental reactions to the first news of their infants' deficiency. Acta Phaediatr Scand 1985;74:787-93.
159. 1 antitripsin deficiency. Clinical follow up and parental attitudes towards neonatal screening. Acta Paediatr Scand 198 1;70:171-7.
160. Sorenson JR, Levy HL, Mangione TW, Sepe SJ. Parental response to repeat testing of infants with 'false-positive' results in a newborn screening program. Pediatrics 1984;73:183-7.
161. Rothenberg MB, Sills EM. Iatrogenesis: the PKU anxiety syndrome. J Am Acad Child Psychol 1968, 7:689-92.
162. Thelin T, McNeil T-E, Aspegren-Jansson E, Sveger T. Identifying children at high somatic risk: possible long-term effects on the parents' attitudes toward themselves as parents and toward having more children. Acta Psychiatr Scand 1985;72:74-80.
163. Thelin T, McNeil TF Aspegren-Jansson E, Sveger T. Identifying children at high somatic risk: possible long-term effects on the parents'views of their own health and current life situation. Acta Paediatr Scand 1985;71:644-53.
164. Dudding T, Wilcken B, Burgess B, Hambly J, Turner G. Reproductive decisions after neonatal screening identifies cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 2000;82:124-7.
165. Bryant LD, Green JM, Hewison J. Prenatal screening for Down's syndrome: some psychosocial implications of a 'screening for all' policy. Publ Health 2001;115:356-8.
166. Green JM, Statham H, Snowdon C. Screening for fetal abnormalities: attitudes and experiences. In Chard T, Richards MPM, editors. Obstetrics in the 1990's: current controversies. London: McKeith Press; 1992. pp. 65-89.
167. Connor M, Norman P. Predicting health behaviour. Milton Keynes: Open University Press; 1996.
168. Green, JM. Genetic screening: something for everyone (including psychologists). Introductory paper given to a symposium on genetic screening at the Annual Conference of the British Psychological Society, University of Warwick, 1-4 April 1995. Summarised in The Psychologist, 1995;8:305-6.
169. National Institute for Clinical Excellence. Antenatal care: routine care for the healthy pregnant woman. Clinical Guideline 6. London: National Institute for Clinical Excellence; 2003.
170. Department of Health. The NHS Plaw a plan for investment, a plan for reform. London: Stationery Office; 2000.
171. Department of Health. The national service framework for children, young people and maternity services - emerging findings. London: Stationery Office 2003.